Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Romania HHC company raided and sanctioned…
  • Ohio - United States Cannabis legalisation ballot initiative gets Senate committee approval…
  • Germany Final reading of the Cannabis Bill is postponed…
  • New York - United States Cannabis licence processing resumes after lawsuit settlement…
  • United States CRS memo addresses hemp industry issues in Farm Bill…
  • United States SAFER Banking Act unlikely to be included in end-of-year legislation…
  • Germany Proposed amendment with further changes to Cannabis Act leaked to press…
  • South Africa Call for submissions on Cannabis for Private Purposes Bill…
  • New Hampshire - United States No further forward on how to regulate recreational cannabis…
  • Australia Victoria open to discuss decriminalisation of personal use…
  • Brazil Public hearing tomorrow on regulation of cannabis/hemp production…
  • Germany Product alert bans sales of e-cig containing cannibinoids…
View all
News analysis

UK’s draft medical guidelines give little support to CBD or cannabis

Written by || 16th August 2019 || News analysis | Health and science | Policy and Politics | GeographiesEngland Europe United Kingdom

The panel responsible for recommending which drugs England’s National Health Service (NHS) should prescribe may recommend against the organisation using cannabis-based medical products. The National Institute for Health and Care Excellence (NICE) has issued draft guidelines which say that in many cases, medical cannabis is both too expensive to be cost-effective and not well-researched enough to be recommended.

Read full article

Download the full news analysis

“UK’s draft medical guidelines give little support to CBD or cannabis”








    I'm already a subscriber

    Login

    Author default picture

    CannIntelligence

    This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

    Our Key Benefits

    The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

    CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

    • Stay informed of any legal and market change in the sector that impacts your organisation
    • Maximise resources by getting market and legal data analysis daily in one place
    • Make smart decisions by understanding how the regulatory and market landscape evolves
    • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

    Thanks for getting in touch with us

    Please leave your enquiry and we will get back to you within 24 hours


      Sign up to our newsletter

      Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


        See more


        By signing up you agree to our Privacy Policy.